arrow
G

Gabriel Tinoco

The Ohio State University
H指数:17
被引数:1,437

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial

维美替尼在腱鞘巨细胞瘤患者中的长期疗效、临床结局及安全性:MOTION III期试验结果

2026-10-190
OAAI
Correction: Tinoco et al. Clear Cell and Histiocytic/Dendritic Cell Sarcomas: Clinical Outcomes, Molecular Features, and Diagnostic Pitfalls. Cancers 2026, 18, 641

更正:Tinoco等人. 透明细胞和组织细胞/树突状细胞肉瘤:临床结局、分子特征和诊断陷阱. Cancers 2026, 18, 641

Cancers
IF4.4
2026-07-280
OA
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial

针对琥珀酸脱氢酶缺陷型胃肠道间质瘤的成纤维细胞生长因子受体抑制:一项2期临床试验

2026-05-260
OAAI
Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome–immune cell signatures

质子泵抑制剂对免疫疗法的影响受先前化疗的调节,并与肠道微生物组–免疫细胞特征相关联

2026-03-090
OAAI
Genomic, transcriptomic, and immunogenomic landscape of over 1300 sarcomas of diverse histology subtypes

超过1300例不同组织学亚型的肉瘤的基因组、转录组及免疫基因组景观

2025-05-060
OA
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial

奥拉帕尼治疗难治性异柠檬酸脱氢酶1 (IDH1) 和IDH2-mutant胆管癌: 来自美国国家癌症研究所10129期2试验的安全性和抗肿瘤活性

CANCER
IF5.1
2025-02-070
PRE
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial

pembrolizumab,放射治疗和手术与放射治疗和手术治疗肢体III期软组织肉瘤的安全性和有效性 (SU2C-SARC032): 一项开放标签,随机临床试验

LANCET
IF88.5
2024-11-010
PRE
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, doubleblind, placebo-controlled, phase 3 trial
LANCET
IF88.5
2024-06-013
PRE
Epithelial-mesenchymal-transition gene signature changes and poor oncological outcome in Candida-positive pancreatic ductal adenocarcinoma
2024-03-220
PRE
A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma
2024-03-063
PRE
NCI 10129: A Phase 2 Study of the PARP inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant advanced solid tumors
2023-12-012
PRE